

that expended for the preceding fiscal year. Funds received under Title I may not be used in maintaining the required level of expenditures;

- That the EMA has an HIV health services planning council and has entered into intergovernmental agreements with any required political subdivisions and has developed or will develop a comprehensive plan for the organization and delivery of health services, in accordance with the legislation;

- That entities within the EMA that receive Title I funds will participate in an established HIV community-based continuum of care if such continuum exists within the EMA;

- That Title I funds will not be utilized to make payments for any item or service to the extent that payment has been made, or can reasonably be expected to be made, with respect to that item or service (1) under any State compensation program, under an insurance policy, or under any Federal or State health benefits program, or (2) by an entity that provides health services on a prepaid basis; and

- To the maximum extent practicable, that HIV health care and support services provided with Title I assistance will be provided without regard to the ability of the individual to pay for such services or to the current or past health condition of the individual. Such services will be provided in a setting that is accessible to low-income individuals with HIV disease, and a program of outreach will be provided to inform such individuals of such services.

- o That the applicant has participated, or will agree to participate, in the statewide coordinated statement of need process where it has been initiated by the State public health agency responsible for administering grants under part B, and ensures that the services provided under the comprehensive plan are consistent with the statewide coordinated statement of need.

General Use of Grant Funds

EMAs must use the Title I HIV Emergency Relief grants to provide financial assistance to public or nonprofit entities, or private for-profit entities if such entities are the only available provider of quality HIV care in the area, for the purpose of delivering or enhancing—

- o HIV-related outpatient and ambulatory health and support services, including case management, substance abuse treatment and mental health treatment, and comprehensive treatment services, which will include treatment

education and prophylactic treatment for opportunistic infections, for individuals and families with HIV disease; and

- o HIV-related inpatient case management services that prevent unnecessary hospitalization or that expedite discharge, as medically appropriate, from inpatient facilities.

In order to provide health and support services to infants, children, and women with HIV disease, including treatment measures to prevent the perinatal transmission of HIV, the EMA must use an amount of funding from the Title I grant not less than the percentage constituted by the ratio of the population in the EMA of infants, children, and women with AIDS to the general population of AIDS-infected individuals in the EMA.

Federal Smoke-Free Compliance

The Public Health Service strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-277, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or, in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children.

Executive Order 12372

Grants awarded for the Title I HIV Emergency Relief Grant Program are subject to the provisions of Executive Order 12372, as implemented under 45 CFR Part 100, which allows States the option of setting up a system for reviewing applications within their States for assistance under certain Federal programs. The application packages made available by HRSA to the EMAs contained a listing of States which have chosen to set up such a review system and provided a point of contact in the States for the review.

(The catalog of Federal Domestic Assistance Numbers are: Formula Grants—93.915; Supplemental Grants—93.914.)

Dated: November 21, 1997.

Claude Earl Fox,

Acting Administrator.

[FR Doc. 97-31210 Filed 11-26-97; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Council Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), announcement is made of the following National Advisory bodies scheduled to meet during the month of December, 1997.

Name: Advisory Commission on Childhood Vaccines (ACCV).

Date and Time: December 3, 1997; 9:00 a.m.–5:00 p.m., December 4, 1997; 9:00 a.m.–12:00 Noon

Place: Parklawn Building, Conference Room D, 5600 Fishers Lane, Rockville, Maryland 20857.

The meeting is open to the public.

The full Commission will meet on Wednesday, December 3, from 9:00 a.m. to 5:00 p.m. and on Thursday, December 4, from 9:00 a.m. to 12:00 p.m. Agenda items will include, but not be limited to: an update on the Vaccine Information Statements for newly added vaccines to the National Vaccine Injury Compensation Program (VICP); a discussion of potential legislative amendments to the VICP; a report on vaccines currently in clinical trials; a presentation on vaccine registries, and reports from the Department of Justice, the National Vaccine Program Office, and routine Program reports.

Public comment will be permitted before lunch and at the end of the Commission meeting on December 3 and before adjournment on December 4. Oral presentations will be limited to 5 minutes per public speaker. Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to: Ms. Melissa Palmer, Principal Staff Liaison, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A-35, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-6593. Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. The Division of Vaccine Injury Compensation will notify each presenter by mail or telephone of their assigned presentation time. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may sign-up in Conference Room D on December 3 and 4. These persons will be allocated time as time permits.

Anyone requiring information regarding the Commission should contact Ms. Palmer, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A-35, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-6593.

Agenda items are subject to change as priorities dictate.

Dated: November 21, 1997.

Jane M. Harrison,

Committee Management Officer, HRSA.

[FR Doc. 97-31221 Filed 11-26-97; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Human Genome Research Institute Initial Review Group, Genome Research Review Subcommittee.

Agenda/Purpose: To review and evaluate grant applications and/or contract proposals.

Date: December 11, 1997.

Time: 1:00 p.m.

Place: Via Teleconference, Building 38A, Room 609, at the National Institutes of Health, Bethesda, MD.

Contact Person: Rudy Pozzatti, Ph.D., Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402-0838.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The applications and/or contract proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalogue of Federal Domestic Assistance Program No. 93.172, Human Genome Research.)

Dated: November 21, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-31230 Filed 11-26-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Meetings

Pursuant to Section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Committee: National Human Genome Research Institute, Special Emphasis Panel ZHG1 (G1).

Agenda/Purpose: To discuss a component of NHGRI's five-year plan.

Date: December 2-3, 1997.

Time: 8:30 a.m.-5:00 p.m.

Place: Chevy Chase Holiday, Chevy Chase, Maryland.

Note: Advanced registration required.

Contact Person: Elise A. Feingold, National Human Genome Research Institute, National Institutes of Health, Building 38A, Room 614, Bethesda, Maryland 20892, (301) 496-7531.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet extramural process requirements.

Name of Committee: National Human Genome Research Institute, Special Emphasis Panel ZHG1 (P1).

Agenda/Purpose: To consider the design issues associated with the development of a repository of cell lines that can be used in the discovery of single nucleotide polymorphisms in human DNA.

Date: December 8-9, 1997.

Time: 8:30 a.m.-5:00 p.m.

Place: Bethesda Marriott Hotel, Pooks Hill, Bethesda, Maryland.

Note: Advanced registration required.

Contact Person: Stephanie Reeves-Walker, National Human Genome Research Institute, National Institutes of Health, Building 38A, Room 614, Bethesda, Maryland 20892, (301) 496-7531.

Meeting Contact Person: Bettie Graham, National Human Genome Research Institute, National Institutes of Health, Building 38A, Room 614, Bethesda, Maryland 20892, (301) 496-7531.

Individuals who plan to attend these meetings and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Elise Feingold or Stephanie Reeves-Walker, (301) 496-7531, two weeks in advance of the meeting.

(Catalogue of Federal Domestic Assistance Program No. 93.172, Human Genome Research.)

Dated: November 19, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-31231 Filed 11-26-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institutes of Child Health and Human Development; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: The Effects of Yoga on Peak Flow Rates in Pregnant Asthmatics (Teleconference).

Date: December 18, 1997.

Time: 3:30 p.m. (ET)—adjournment.

Place: 6100 Executive Boulevard, Room 5E03, Rockville, Maryland 20892.

Contact Person: Norman C. Chang, Ph.D., Scientific Review Administrator, NICHD, 6100 Executive Boulevard, Room 5E03, Rockville, MD 20852, Telephone: 301-496-1485.

Purpose/Agenda: To evaluate and review a grant application.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussion of this application could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institutes of Health, HHS)

Dated: November 21, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-31227 Filed 11-26-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: December 9, 1997.

Time: 2 p.m.